Clinical trial evaluating AN9025 for RAS-mutated solid tumors initiated
A clinical trial is underway to assess the safety and tolerability of AN9025 in patients with RAS-mutated solid tumors.
Asset / Drug
Drug and asset intelligence for AN9025 with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
RAS Inhibitor
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.